Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

The T cell response to SARS-CoV-2 is detected by a PCR assay on whole blood. Fast, high-throughput methods for measuring the level and duration of protective immune responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here we report the development of two quantitative PCR assays for SARS-CoV-2-specific T cell activation. The assays are rapid, internally normalized and probe-based: qTACT requires RNA extraction and dqTACT avoids sample preparation steps. Both assays rely on the quantification of CXCL10 messenger RNA, a chemokine whose expression is strongly correlated with activation of antigen-specific T cells. On restimulation of whole-blood cells with SARS-CoV-2 viral antigens, viral-specific T cells secrete IFN-gamma, which stimulates monocytes to produce CXCL10. CXCL10 mRNA can thus serve as a proxy to quantify cellular immunity. Our assays may allow large-scale monitoring of the magnitude and duration of functional T cell immunity to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.

Automated summary

This study reports the development of two quantitative PCR assays for detecting SARS-CoV-2-specific T cell activation. These assays are rapid, internally normalized, and can quantify the magnitude and duration of cellular immune responses, helping to determine revaccination strategies in vulnerable populations.